When reviewing M&A life sciences deals in 2026, an apparent contradiction arises. Companies are doing fewer deals than they were several years ago, but the amount of money changing hands has risen sharply. Biotechgate data thus far in 2026 shows that transaction volumes remain below the levels seen in 2023, whereas disclosed deal value and median transaction size are considerably higher. In other words, this is not a broad-based acquisition boom. It is a market in which buyers appear increasingly selective, and increasingly willing to pay, when they find the right target.
That raises the more interesting question: why?
Patent cliffs are creating urgency
For big pharmas, one answer is timing. Many of the industry’s biggest products are approaching loss of exclusivity over the coming years, creating pressure to replace future revenue before those sales begin to erode. Developing a successful replacement internally can take a decade or more, and even well-funded R&D pipelines cannot guarantee that the right assets will arrive at the right time.
M&A offers a faster route. Acquiring a company with a later-stage drug, an established commercial product or a platform that complements an existing pipeline can bring future revenue closer while filling gaps that internal research has not addressed.
That pressure is becoming increasingly visible across the industry. PwC has identified pipeline replenishment ahead of looming patent expiries as one of the central drivers of 2026 dealmaking, while IQVIA similarly points to the need to secure future growth assets.
The buyers can afford to act
Urgency alone does not create large transactions. Buyers also need the financial capacity to pursue them. Many major pharmas continue to generate substantial cash flows from existing blockbuster franchises, leaving them with significant capital available for external growth. At the same time, companies are being more deliberate about where that capital goes.
Rather than pursuing scale for its own sake, much of the current activity is targeted at specific therapeutic areas, technologies or late-stage pipeline opportunities that can strengthen an existing strategic position.
Paying more for less uncertainty
The rise in deal values does not necessarily mean buyers are becoming less disciplined. Arguably, it suggests the opposite. The strongest demand is increasingly concentrated around assets that have already cleared some of the major uncertainties of drug development, such as products supported by stronger clinical data, clearer regulatory pathways or existing commercial traction.
An industry preference for de-risked assets is evident. This helps explain why median disclosed transaction values have risen alongside aggregate deal value. Large transactions such as Abbott’s acquisition of Exact Sciences and Blackstone’s agreement to acquire Hologic clearly lift the headline totals, but the broader increase in median deal size suggests the trend is not solely the result of a handful of megadeals.
The pattern is therefore less about buyers taking more risk and more about paying more for less of it.
Selectivity, not indiscriminate dealmaking
The current M&A market looks very different from a simple race to acquire. Buyers are facing growing pressure to strengthen future pipelines, they have capital available to deploy, and many are prepared to pay substantial premiums for assets that offer strategic fit and reduced development risk.
The result is a market characterized by fewer transactions, but larger commitments when buyers decide an opportunity is worth pursuing. With patent-expiry pressure still building and pipeline gaps unlikely to disappear, that selectivity may remain one of the defining features of life sciences M&A into 2027.